Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ARRAY BIOPH	ARMA INC									
Form 4 December 04, 20	00									
									PPROVAL	
FORM 4 UNITED STATES SECURITIES ANI Washington, D.									3235-0287	
Check this boy if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					Estimated a burden hou response	Expires:January 31, 2005Estimated average burden hours per response0.5			
(Print or Type Respo	onses)									
1. Name and Address of Reporting Person <u>*</u> LEFKOFF KYLE			2. Issuer Name and Ticker or Trading Symbol ARRAY BIOPHARMA INC [ARRY]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) 1900 9TH STRE	· / · ·	Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/02/2008				X_ Director 10% Owner Officer (give title Other (specify below) below)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
BOULDER, CO	80302						Form filed by Person	More than One Ro	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficial	lly Owned	
	ansaction Date 1th/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4) Amount	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report or	n a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					Perso inform requir	ns who res nation cont red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

Edgar Filing: ARRAY BIOPHARMA INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	or Dispos (D)	(Instr. 3, 4,					(
			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 3.37	12/02/2008	A	15,000		<u>(1)</u>	12/02/2018	Common Stock	15,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
L O	Director	10% Owner	Officer	Other			
LEFKOFF KYLE 1900 9TH STREET BOULDER, CO 80302	Х						
Signatures							
John D. Maana attamps, in fact for Danarting							

John R. Moore, attorney-in-fact for Reporting Person

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests as to one-third of the underlying shares on each of November 1, 2009, November 1, 2010 and November 1, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

12/04/2008

C